The arduous road to achieving an immunosuppression-free state in kidney transplant recipients

Nature Clinical Practice Nephrology

Volumn 3, Issue 9, 2007, Pages 464-465

  Ansari, M Javeed ^a,b   Sayegh, Mohamed H ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Transplantation Biology Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; RAPAMYCIN; THYMOCYTE ANTIBODY;

GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SURVIVAL; T LYMPHOCYTE;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 34548189213     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0568     Document Type: Short Survey

References (20)

1. Sayegh MH and Carpenter CB (2004) Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 351: 2761-2766
2. Salama AD et al. (2001) Challenges to achieving clinical transplantation tolerance. J Clin Invest 108: 943-948
3. Matthews JB et al. (2003) Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant 3: 794-803
4. Strober S et al. (1989) Acquired immune tolerance to cadaveric renal allografts: a study of three patients treated with total lymphoid irradiation. N Engl J Med 321: 28-33
5. Fudaba Y et al. (2006) Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 6: 2121-2133
6. Sayegh MH et al. (1991) Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 114: 954-955
7. Martinez-Llordella M et al. (2007) Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 7: 309-319
8. Roussey-Kesler G et al. (2006) Clinical operational tolerance after kidney transplantation. Am J Transplant 6: 736-746
9. Calne R et al. (1999) Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68: 1613-1616
10. Kirk AD et al. (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76: 120-129
11. Barth RN et al. (2006) Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 19: 885-892
12. Swanson SJ et al. (2002) Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 360: 1662-1664
13. Starzl TE et al. (2003) Tolerogenic immunosuppression for organ transplantation. Lancet 361: 1502-1510
14. Denton MD et al. (1999) Immunosuppressive strategies in transplantation. Lancet 353: 1083-1091
15. Neujahr DC et al. (2006) Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 176: 4632-4639
16. Sayegh MH and Remuzzi G (2007) Clinical update: immunosuppression minimisation. Lancet 369: 1676-1678
17. Najafian N et al. (2006) How can we measure immunologic tolerance in humans? J Am Soc Nephrol 17: 2652-2663
18. Chen L et al. (2006) TLR engagement prevents transplantation tolerance. Am J Transplant 6: 2282-2291
19. Adams AB et al. (2003) Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111: 1887-1895
20. Cai J et al. (2004) Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 78: 919-924